

DAFTAR PUSTAKA

- Abubakar, A.R., Simbak, N. Bin dan Haque, M., 2014. Adverse Drug Reactions: Predisposing Factors, Modern Classifications and Causality Assessment, *Research Journal Of Pharmacy and Technology*, **7(9)**: 1091–1098.
- Adeoye, M.A., 2023. Review Of Sampling Techniques For Education, *ASEAN Journal for Science Education*, **2(2)**: 87–94, <<https://ejournal.bumipublikasinusantara.id/index.php/ajsed>>.
- Alomar, M.J., 2014. Factors Affecting The Development of Adverse Drug Reactions, *Saudi Pharmaceutical Journal*, **22(2)**: 83–94. <https://doi.org/10.1016/j.jsps.2013.02.003>.
- Ambili Remesh, 2012. Toxicities of Anticancer Drugs and Its Management, *IJBPC International Journal of Basic & Clinical Pharmacology*, **1(1)**: 2–12. <https://doi.org/10.5455/2319-2003.ijbcp000812>.
- Anna, K., Bethania, K.A. dan Rustamadj, P., 2022. Hubungan Subtipe Molekular pada Karsinoma Payudara Invasif dengan Grade, Invasi Limfovaskular dan Metastasis KGB, *Departemen Patologi Anatomi FKUI / RSCM*, pp 92–399.
- Anwar, S.L., Cahyono, R., Prabowo, D., Avanti, W.S. dan Choridah, L., 2021. Metabolic Comorbidities And The Association With Risks Of Recurrent Metastatic Disease In Breast Cancer Survivors, *BMC Cancer*, **21**: 1–13.
- Anwer, R.A., Ghafor, S. dan Ahmad, H., 2022. Neoadjuvant Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel in Triple-Negative, Early-Stage Breast Cancer, *PJMHS*, **16(8)**: 2021–2023.
- Bayles, C.E., Hale, D.E., Konieczny, A., Anderson, V.D., Richardson, C.R., Brown, K. V., dkk, 2023. Upcycling The Anthracyclines: New Mechanisms of Action, Toxicology, and Pharmacology, *Toxicology and Applied Pharmacology*, **15(1)**: 1–22. <https://doi.org/10.1016/j.taap.2022.116362> 459.
- BC-Cancer, 2013. DRUG NAME : Cyclophosphamide, *BC Cancer Drug Manual*, pp 1–12.
- BC-Cancer, 2019a. DRUG NAME : Cisplatin, *BC Cancer Drug Manual*, pp 1–11.
- BC-Cancer, 2019b. DRUG NAME : Paclitaxel, *BC Cancer Drug Manual*.
- BC-Cancer, 2021. DRUG NAME: Docetaxel, *BC Cancer Drug Manual*, pp 1–13.
- BC-Cancer, 2024. DRUG NAME : Carboplatin, *BC Cancer Drug Manual*.
- BC-Cancer, 2025a. DRUG NAME : Doxorubicin, *BC Cancer Drug Manual*, pp 1–12.
- BC-Cancer, 2025b. DRUG NAME : Epirubicin, *BC Cancer Drug Manual*, pp 1–9.
- Behera, S.K., Das, S., Xavier, A.S., Velupula, S. dan Sandhiya, S., 2018. Comparison Of Different Methods For Causality Assessment Of Adverse Drug Reactions, *International Journal of Clinical Pharmacy*, **40(4)**: 903–910, <https://doi.org/10.1007/s11096-018-0694-9>.
- Beretta, G.L. dan Zunino, F., 2007. Molecular Mechanisms of Anthracycline Activity, *Topics in Current Chemistry*, pp 1–19.

- https://doi.org/10.1007/128_2007_3.
- Booster, B.L., Patel, N.K. dan Kaushik, J., 2023. 'Breast Cancer' in Dipiro, J. dkk, *Dipiro's Pharmacotherapy: A Pathophysiologic Approach*, 12th ed., McGraw Hill, United States.
- BPOM, 2020. Modul Farmakovigilans Untuk Tenaga Profesional Kesehatan Proyek "Ensuring Drug and Food Safety," *Badan Pengawas Obat dan Makanan (BPOM) RI*, pp 29–36.
- Bunnell, B.A., Martin, E.C., Matossian, M.D., Brock, C.K., Nguyen, K., Collins, B., dkk, 2022. The Effect of Obesity on Adipose - Derived Stromal Cells and Adipose Tissue and Their Impact on Cancer, *Cancer and Metastasis Reviews*, pp 549–573. <https://doi.org/10.1007/s10555-022-10063-1>.
- Carey, P.J., 2003. Drug-Induced Myelosuppression Diagnosis and Management, *Drug Safety*, **26(10)**: 691–706.
- Chan, J., Adderley, H., Alameddine, M., Armstrong, A., Arundell, D., Fox, R., dkk, 2020. Permanent Hair Loss Associated With Taxane Chemotherapy Use In Breast Cancer : A Retrospective Survey At Two Tertiary UK Cancer Centres, *European Journal Cancer Care*, pp 1–8. <https://doi.org/10.1111/ecc.13395>.
- Chatterjee, K., Zhang, J., Honbo, N. dan Karliner, J.S., 2010. Doxorubicin Cardiomyopathy, *Cardiology*, pp 155–162. <https://doi.org/10.1159/000265166>.
- Choudhary, R., Poonia, S., Punia, D.P., Maheshwari, R., Mathur, K.C. dan Adv, J.P.P., 2012. Platinum Compounds-Induced renal and Bone Marrow Toxicity : a Review, *Journal of Physiology and Pharmacology Advances*, **2(3)**: 145–149.
- Cordes, L.M. dan Cuellar, S., 2013. *Cancer: The Disease And Treatment'* in Dipiro, J. dkk, *Dipiro's Pharmacotherapy: A Pathophysiologic Approach*, 12th ed., McGraw Hill, United States.
- Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J.P., Wolmark, N. dan dkk, 2014. Pathological Complete Response And Long-Term Clinical Benefit In Breast Cancer: The Ctnobc Pooled Analysis, *The Lancet*, pp 164–172. [https://doi.org/10.1016/S0140-6736\(13\)62422-8](https://doi.org/10.1016/S0140-6736(13)62422-8).
- Curtis, B.R., 2017. Non – Chemotherapy Drug – Induced Neutropenia : Key Points To Manage The Challenges, *Hematology*, pp 187–193.
- Dale, D.C., 2025. Neutropenia (Agranulocytosis; Granulocytopenia), *Hematology and Oncology*, pp 1-13.
- Daly, M.E., 2011. Determinants Of Platelet Count In Humans, *Haematologica*, pp 12–15. <https://doi.org/10.3324/haematol.2010.035287>.
- Dent, R., Trudeau, M., Pritchard, K.I., Hanna, W.M., Kahn, H.K., Sawka, C.A., dkk, 2007. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence, *Clinical Cancer Research*, pp 4429–4434. <https://doi.org/10.1158/1078-0432.CCR-06-3045>.
- Donegal, C., 2006. Management Of Chemotherapy-Induced Nausea And Vomiting, *British Journal of Hospital Medicine*, **67(8)**: 410–413.
- Dubia, R., Konieczna, A., Poleszczuk, J., Pawlik, H. dan Rosi, M., 2024. Retrospective Observational Study to Determine the Epidemiology and

- Treatment Patterns of Patients with Triple-Negative Breast Cancer, *Cancers*, 16:1087. <https://doi.org/10.3390/cancers16061087>.
- FDA, 2018. Clinical Trial Endpoints for The Approval of Cancer Drugs and Biologics: Guidance for Industry, *U.S. Food and Drug Administration*, pp 1–16.
- Feng, W., He, Y., Xu, J., Zhang, H. dan Si, Y., 2021. A Meta-Analysis of The Effect and Safety of Platinum-Based Neoadjuvant Chemotherapy In Treatment of Resectable Triple-Negative Breast Cancer, *Anti-Cancer Drugs*, pp 52–60. <https://doi.org/10.1097/CAD.0000000000001196>.
- Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., dkk, 2024. Cancer Statistics For The Year 2020: An Overview, *International Journal Cancer*, **149(4)**: 778–789. <https://doi.org/10.1002/ijc.33588>.
- Fisusi, F.A., 2019. Drug Combinations in Breast Cancer Therapy, *Pharmaceutical Nanotechnology*, pp 3–23. <https://doi.org/10.2174/2211738507666190122111224>.
- Giffoni, D., Morais, D.M., Pezo, R.C., Chan, K.K.W., Menjak, I., Eisen, dkk., 2025. A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline – Taxane Chemotherapy in Early HER-2 Negative Breast Cancer, pp 1–20.
- Gilbert, A., Piccinin, C., Velikova, G., Groenvold, M., Kuliś, D., Blazeby, J.M. dkk, 2022. Linking the European Organisation for Research and Treatment of Cancer Item Library to the Common Terminology Criteria for Adverse Events, *Journal of Clinical Oncology*, **40(32)**: 3770–3780. <https://doi.org/10.1200/JCO.21.02017>.
- Giselle, C., Nara, F.P., Fernandes, E.S., Maria, L.C.B.M. dan Campos, M., 2020. Taxane-Induced Neurotoxicity : Pathophysiology And Therapeutic Perspectives, *British Pharmacological Society*, pp 3127–3146. <https://doi.org/10.1111/bph.15086>.
- Gogia, A., Raina, V., Deo, S.V., Shukla, N.K., Mohanti, B.K. dan Sharma, D.N., 2014. Taxane and Anthracycline Based Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer : Institutional Experience, *Asian Pacific Journal of Cancer Prevention*, **15(5)**: 1989–1992. <https://doi.org/10.7314/APJCP.2014.15.5.1989>.
- Hafsah, L., 2022. Gambaran Tingkat Kecemasan Pada Pasien Kanker Yang Menjalani Kemoterapi di RSUD Dr. M. Yunus Bengkulu, *Jurnal Vokasi Keperawatan*, **5(1)**: 21–28. <https://doi.org/10.33369/jvk.v5i1.22338>.
- Han, H.S., Vikas, P., Costa, R.L.B., Jahan, N. dan Taye, A., 2023. Early-Stage Triple-Negative Breast Cancer Journey : Beginning, End and Everything in Between, *American Society of Clinical Oncology*, pp 1–12.
- Hartaningsih, N.M.D. dan Sudarsana, I.W., 2014. Kanker Payudara pada Wanita Usia Muda di Bagian Bedah Onkologi Rumah Sakit Umum Pusat Sanglah Denpasar Tahun 2002–2012, *E-Jurnal Medika Udayana*, **3(6)**: 1–13.
- Hermansyah, D., Rahayu, Y., Azrah, A., Pricilia, G., Rifsal, D. dan dkk., 2021. Triple-Negative Breast Cancer Clinicopathology: A Single-Center

- Experience, *Indonesian Journal of Cancer*, **15(3)**: 125–128.
<https://doi.org/10.33371/ijoc.v15i3.791>.
- Hill, C. dan Carolina, N., 2019. Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?, *The Oncologist*, **24(11)**: 1469–1478.
<https://doi.org/10.1634/theoncologist.2019-0175>.
- Hima, N.A., Andrajati, R. dan Radji, M., 2021. Kejadian Demam Neutropenia pada Pasien Kanker Payudara setelah Menerima Regimen Kemoterapi TAC-G-CSF dan FAC di RSUP Dr. Hasan Sadikin Bandung, *Indonesian Journal of Clinical Pharmacy*, **10(1)**: 1–10.
<https://doi.org/10.15416/ijcp.2021.10.1.1>.
- Hirano, A., Shimizu, T., Watanabe, O., Kinoshita, J., Kimura, K., Kamimura, M. dan dkk., 2008. Epirubicin and Cyclophosphamide Followed by Docetaxel as Primary Systemic Chemotherapy in Locally Advanced Breast Cancer, *Anticancer Research*, **28(6)**: 4137–4142.
- Ho, M.Y. dan Mackey, J.R., 2014. Presentation and Management of Docetaxel-Related Adverse Effects in Patients with Breast Cancer, *Cancer Management and Research*, **6(1)**: 253–259.
<https://doi.org/10.2147/CMAR.S40601>.
- Hsu, C., Huang, C.S., Chao, T.Y., Lu, Y.S., Bu, C.F., Chen, M.M. dan dkk., 2002. Phase II Trial Combining Paclitaxel with 24-Hour Infusion Cisplatin for Chemotherapy-Naïve Patients with Locally Advanced or Metastatic Breast Carcinoma, *Cancer*, **95(10)**: 2044–2050.
<https://doi.org/10.1002/cncr.10951>.
- Huang, Q., Feng, L., Li, H., Zheng, L., Qi, X. dan Wang, Y., 2020. Jian-Pi-Bu-Xue-Formula Alleviates Myelosuppression via Up-Regulating, *Frontiers in Pharmacology*, **11**: 1–15. <https://doi.org/10.3389/fphar.2020.01302>.
- Huang, W., Wang, C., Wang, L., Shen, Y., Chen, Q., Huang, Z. dan dkk., 2024. Feasibility and Tolerability of Eribulin-Based Chemotherapy versus Other Chemotherapy Regimens for Patients with Metastatic Triple-Negative Breast Cancer: A Single-Centre Retrospective Study, *Frontiers in Cell and Developmental Biology*, **12**.
<https://doi.org/10.3389/fcell.2024.1313610>.
- Icanervilia, A.V., Choridah, L., Asselt, A.D.I. van, Vervoort, J.P.M., Postma, M.J., Rengganis, A.A. dan dkk., 2023. Early Detection of Breast Cancer in Indonesia: Barriers Identified in a Qualitative Study, *Asian Pacific Journal of Cancer Prevention*, **24(8)**: 2749–2755.
<https://doi.org/10.31557/APJCP.2023.24.8.2749>.
- Imran, M., Saleem, S., Chaudhuri, A., Ali, J. dan Baboota, S., 2020. Docetaxel: An Update on Its Molecular Mechanisms, Therapeutic Trajectory and Nanotechnology in the Treatment of Breast, Lung and Prostate Cancer, *Journal of Drug Delivery Science and Technology*, **60**: 101959.
<https://doi.org/10.1016/j.jddst.2020.101959>.
- Jan, N., Sofi, S., Qayoom, H., Shabir, A., Haq, B.U., Macha, M.A. dan dkk., 2024. Metronomic Chemotherapy and Drug Repurposing: A Paradigm Shift in Oncology, *Heliyon*, **10(3)**: 24670.

- <https://doi.org/10.1016/j.heliyon.2024.e24670>.
- Jati, F.H., Khambri, D. dan Mulyani, H., 2025. Respons Kemoterapi terhadap Kanker Payudara Triple Negative di RSUP Dr. M. Djamil Padang.
- Jivani, A. dan Shinde, R.K., 2024. A Comprehensive Review of Taxane Treatment in Breast Cancer: Clinical Perspectives and Toxicity Profiles, *Cureus*, **16(4)**. <https://doi.org/10.7759/cureus.59266>.
- Kaur, S., Mayanglambam, P., Bajwan, D. dan Thakur, N., 2022. Chemotherapy and its Adverse Effects – A Systematic Review, *International Journal of Nursing Education and Research*, pp 399–402. <https://doi.org/10.52711/2454-2660.2022.00090>.
- Kementerian Kesehatan Republik Indonesia, 2018. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/414/2018 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara, **3(2)**: 91–102.
- Kementerian Kesehatan Republik Indonesia, 2024. Rencana Kanker Nasional, pp 2024–2034.
- Kenar, G., 2020. Prevalence, Etiology and Risk Factors of Anemia in Patients with Newly Diagnosed Cancer, pp 5235–5242.
- Kennedy, C.R., Gao, F., Ph, D. dan Margenthaler, J.A., 2010. Neoadjuvant Versus Adjuvant Chemotherapy for Triple Negative Breast Cancer, *Journal of Surgical Research*, **163(1)**: 52–57. <https://doi.org/10.1016/j.jss.2010.04.015>.
- Khanna, M., Kaur, K., Manjari, M. dan Khanna, A., 2016. Ki67 Expression in Triple Negative Breast Cancer: Correlation of Ki67 Expression with Other Prognostic Factors in Breast Cancer in Indian Patients, **2(2)**: 76–81.
- Khasraw, M., Bell, R. dan Dang, C., 2012. Epirubicin: Is It Like Doxorubicin in Breast Cancer? A Clinical Review, *The Breast*, **21(2)**: 142–149. <https://doi.org/10.1016/j.breast.2011.12.012>
- Kolářová, I., Melichar, B., Sirák, I., Vaňásek, J. dan Petera, J., 2024. The Role of Adjuvant Radiotherapy in the Treatment of Breast Cancer. <https://doi.org/10.20944/preprints202401.1340.v1>.
- Li, Z., Zhang, Z. dan Cao, X., 2020. Platinum-Based Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. <https://doi.org/10.1177/0300060520964340>.
- Li, Z., Zheng, J., Ji, Z., Chen, L., Wu, J., Zou, J. dan dkk., 2022. Addition of Capecitabine to Adjuvant Chemotherapy May Be the Most Effective Strategy for Patients with Early-Stage Triple-Negative Breast Cancer: A Network Meta-Analysis of 9 Randomized Controlled Trials, *Frontiers in Endocrinology*, **13**: 1–11. <https://doi.org/10.3389/fendo.2022.939048>.
- Lim, R., Ellett, L.K., Roughead, E.E., Cheah, P.Y. dan Masnoon, N., 2021. Patient-Reported Questionnaires to Identify Adverse Drug Reactions: A Systematic Review, *International Journal of Environmental Research and Public Health*, **18(22)**. <https://doi.org/10.3390/ijerph182211877>.
- Lin, N.U., Vanderplas, A., Hughes, M.E., Theriault, R.L., Edge, S.B., Wong, Y.N.

- dan dkk., 2012. Clinicopathologic Features, Patterns of Recurrence, and Survival among Women with Triple-Negative Breast Cancer in the National Comprehensive Cancer Network, *Cancer*, **118(22)**: 5463–5472. <https://doi.org/10.1002/cncr.27581>.
- Loibl, S., André, F., Bachelot, T., Barrios, C., Bergh, J., H., B. dan dkk., 2024. Early Breast Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up, *Annals of Oncology*, **35(2)**. <https://doi.org/10.1016/j.annonc.2023.11.016>.
- Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W.M., Rugo, H.S., McKee, M.D. dan dkk., 2018a. Addition of the PARP Inhibitor Veliparib plus Carboplatin or Carboplatin Alone to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer (BrighTNess): A Randomised, Phase 3 Trial, *The Lancet Oncology*, **19(4)**: 497–509. [https://doi.org/10.1016/S1470-2045\(18\)30111-6](https://doi.org/10.1016/S1470-2045(18)30111-6).
- Loibl, S., Weber, K.E., Timms, K.M., Elkin, E.P., Hahnen, E., Fasching, P.A. dan dkk., 2018b. Survival Analysis of Carboplatin Added to an Anthracycline/Taxane-Based Neoadjuvant Chemotherapy and HRD Score as Predictor of Response: Final Results from GeparSixto, *Annals of Oncology*, **29(12)**: 2341–2347. <https://doi.org/10.1093/annonc/mdy460>.
- Lorange, J.-P., Ramirez Garcia Luna, J., Grou-Boileau, F., Rosenzweig, D., Weber, M.H. dan Akoury, E., 2023. Management of Bone Metastasis with Zoledronic Acid: A Systematic Review and Bayesian Network Meta-Analysis, *Journal of Bone Oncology*, **39**: 100470. <https://doi.org/10.1016/j.jbo.2023.100470>.
- Lwanga, S.K. dan Lemeshow, S., 1991. *Sample Size Determination in Health Studies*. Geneva: World Health Organization.
- Macciò, A., Madeddu, C., Gramignano, G., Mulas, C., Tanca, L., Cherchi, M.C. dan dkk., 2015. The Role of Inflammation, Iron, and Nutritional Status in Cancer-Related Anemia: Results of a Large, Prospective, Observational Study, *Haematologica*, **100(1)**. <https://doi.org/10.3324/haematol.2014.112813>.
- Mackey, J.R., Martin, M., Pienkowski, T., Rolski, J., Guastalla, J.P., Sami, A. dan dkk., 2013. Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide in Node-Positive Breast Cancer: 10-Year Follow-Up of the Phase 3 Randomised BCIRG 001 Trial, *The Lancet Oncology*, **14(1)**: 72–80. [https://doi.org/10.1016/S1470-2045\(12\)70525-9](https://doi.org/10.1016/S1470-2045(12)70525-9).
- Maimora, F., Ifora, I. dan Kardela, W., 2020. Adverse Drug Reactions of Platinum Analogs: A Review, **32(5)**: 527–531.
- Manohar, H.D., Bairy, K.L. dan Thomas, J., 2015. Pattern of Adverse Drug Reactions due to Cancer Chemotherapy in a Tertiary Care Hospital in South India, *Journal of Young Pharmacists*, **6(2)**: 109–115. <https://doi.org/10.4103/2229-3485.154014>.
- Masuda, N., Bando, H., Yamanaka, T., Kadoya, T., Takahashi, M., Nagai, S.E. dan dkk., 2021. Eribulin-Based Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer Patients Stratified by Homologous

- Recombination Deficiency Status: A Multicenter Randomized Phase II Clinical Trial, *Breast Cancer Research and Treatment*, **188(1)**: 117–131. <https://doi.org/10.1007/s10549-021-06184-w>.
- Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M. dan dkk., 2014. Neoadjuvant Carboplatin in Patients with Triple-Negative and HER2-Positive Early Breast Cancer (GeparSixto; GBG 66): A Randomised Phase II Trial, *The Lancet Oncology*, **15(7)**: 747–756. [https://doi.org/10.1016/S1470-2045\(14\)70160-3](https://doi.org/10.1016/S1470-2045(14)70160-3).
- Mittal, A., Agrawal, A., Chandragouda, S.B. dan Quareshi, S., 2021. Chemotherapy Toxicity in Elderly Population ≥ 65 Years: A Tertiary Care Hospital Experience from India, *Indian Journal of Medical and Paediatric Oncology*: 531–535. <https://doi.org/10.4103/ijmpo.ijmpo>.
- Mudigubba, M.K., Murthy, M.K., Swaroop, A.M., Nayantara, M. dan Dahiya, S., 2018. A Systematic Review of Risk Factors of Adverse Drug Reactions in Hospitalized Patients, *Asian Journal of Pharmaceutical and Clinical Research*, **11(10)**: 25–29. <https://doi.org/10.22159/ajpcr.2018.v11i10.27759>.
- National Comprehensive Cancer Network (NCCN), 2024. *Breast Cancer: Invasive*. NCCN Clinical Practice Guidelines in Oncology.
- Ng, B., Puspitaningtyas, H., Wiranata, J.A., Hutajulu, S.H., Widodo, I., Anggorowati, N. dan dkk., 2023. Breast Cancer Incidence in Yogyakarta, Indonesia from 2008–2019: A Cross-Sectional Study Using Trend Analysis and Geographical Information System, *PLoS ONE*, **18(7)**: 1–17. <https://doi.org/10.1371/journal.pone.0288073>.
- NHS, 2018. Chemotherapy Protocol Breast Cancer: Docetaxel, Doxorubicin and Cyclophosphamide, *National Health Service United Kingdom*, 1(January), pp 1–5.
- NHS, 2020a. Chemotherapy Protocol Breast Cancer: Doxorubicin, Cyclophosphamide and Paclitaxel, *National Health Service United Kingdom*, 1.2(October), pp 1–8.
- NHS, 2020b. Chemotherapy Protocol Breast Cancer: Epirubicin, Cyclophosphamide and Paclitaxel, *National Health Service United Kingdom*, 1.2(November), pp 1–7.
- NHS, 2022a. Chemotherapy Protocol Breast Cancer: Carboplatin-Docetaxel, *National Health Service United Kingdom*, 1.1(Aug), pp 1–8.
- NHS, 2022b. Chemotherapy Protocol Breast Cancer: Carboplatin-Paclitaxel, *National Health Service United Kingdom*, 1.2(Aug), pp 1–8.
- NHS, 2025. Chemotherapy Protocol Breast Cancer: Epirubicin, Cyclophosphamide and Docetaxel, *National Health Service United Kingdom*, 1(April), pp 1–5.
- Pádua, C. de, Ana, S., Barroso, S., Ana, C., Oliveira, C. de, Carvalho, D. dan dkk., 2023. Neoadjuvant Carboplatin in Triple-Negative Breast Cancer: Results from NACATRINE, a Randomized Phase II Clinical Trial, *Breast Cancer Research and Treatment*, **202(1)**: 57–65. <https://doi.org/10.1007/s10549-023-07011-0>.
- Pagani, M., Bavbek, S., Adile, C., Dursun, B., Bonadonna, P., Castells, M. dan dkk.,

2022. Hypersensitivity Reactions to Chemotherapy: An EAACI Position Paper, *Allergy*: 388–403. <https://doi.org/10.1111/all.15113>.
- Palanisamy, S., Kumaran, K.S.A. dan Rajasekaran, A., 2011. A Study on Assessment, Monitoring and Reporting of Adverse Drug Reactions in Indian Hospital, *Asian Journal of Pharmaceutical and Clinical Research*, **4(3)**: 112–116.
- Pawar, P.A., Deshmukh, T.A. dan Naik, J.B., 2022. Evaluation and Assessment of Adverse Drug Reactions at a Tertiary Care Hospital, *International Journal of Health Sciences*, **6**: 6938–6946. <https://doi.org/10.53730/ijhs.v6ns2.6734>.
- Pham, T.D. dan Tsunoyama, T., 2024. Exploring Extravasation in Cancer Patients, *Cancer*, **16**: 1–26.
- Poggio, F., Bruzzone, M., Ceppi, M., Pondé, N.F., La Valle, G., Del Mastro, L. dan dkk., 2018. Platinum-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis, *Annals of Oncology*, **29(7)**: 1497–1508. <https://doi.org/10.1093/annonc/mdy127>.
- Primadanti, S.J. dan Setiawan, I.G.B., 2018. Prevalensi Kanker Payudara Subtipe Triple Negative pada Wanita Usia Muda di Bali Periode Januari 2014–Oktober 2016: 87–90.
- Roy, V., Pockaj, B.A., Allred, J.B., Apsey, H., Northfelt, D.W., Nikcevich, D. dan dkk., 2013. A Phase II Trial of Docetaxel and Carboplatin Administered Every 2 Weeks as Preoperative Therapy for Stage II or III Breast Cancer: NCCTG Study N0338, *American Journal of Clinical Oncology*, **36(6)**: 540–544. <https://doi.org/10.1097/COC.0b013e318256f619>.
- Sahoo, D., Deb, P., Basu, T., Bardhan, S., Patra, S. dan Sukul, P.K., 2024. Advancements in Platinum-Based Anticancer Drug Development: A Comprehensive Review of Strategies, Discoveries, and Future Perspectives, *Bioorganic & Medicinal Chemistry*, **112**: 117894. <https://doi.org/10.1016/j.bmc.2024.117894>.
- Sangeetha, K.S.S., 2025. Efficacy of Neoadjuvant vs. Adjuvant Chemotherapy in Triple-Negative Breast Cancer: A Meta-Analysis, **32(11)**: 2062–2068.
- Setiaji, M.M. dan Choliso, Z., 2025. Analysis of Adverse Drug Reactions (ADRs) and Their Severity in Breast Cancer Patients Treated with the Docetaxel–Doxorubicin Regimen, *Jurnal Farmasi Sains dan Praktis*, **11(2)**: 92–103.
- Sharma, P., Kimler, B.F., O’Dea, A., Nye, L., Wang, Y.Y., Yoder, R. dan dkk., 2021. Randomized Phase II Trial of Anthracycline-Free and Anthracycline-Containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-Negative Breast Cancer (NeoSTOP), *Clinical Cancer Research*, **27(4)**: 975–982. <https://doi.org/10.1158/1078-0432.CCR-20-3646>.
- Sihombing, B.A. dan Batubara, C.A., 2024. Anemia Profile in Cancer Patients at Adam Malik Hospital for the Period June 2022 to May 2023, *Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI)*, **6(3)**: 7–12. <https://doi.org/10.32734/jetromi.v6i3.14957>.

- Singh, P., Jaiswal, A., Khurana, A., Singh, J. dan Navik, U., 2021. Biomedicine & Pharmacotherapy Doxorubicin-Induced Cardiotoxicity : An Update on The Molecular Mechanism and Novel Therapeutic Strategies For Effective Management, *Biomedicine & Pharmacotherapy*, 139, pp 1–14. <https://doi.org/10.1016/j.biopha.2021.111708>.
- Siwi, A.S., Sumarni, T., Fadly, A.R. dan Hidayat, A.I., 2021. Kualitas Hidup pada Pasien Kanker yang Menjalani Kemoterapi: 340–3347.
- Škubník, J., Pavličková, V., Ruml, T. dan Rimpelová, S., 2021. Current Perspectives on Taxanes: Focus on Their Bioactivity, Delivery and Combination Therapy, *Plants*, **10(3)**: 1–35. <https://doi.org/10.3390/plants10030569>.
- Sun, Y., Liu, Y., Ma, X. dan Hu, H., 2021. The Influence of Cell Cycle Regulation on Chemotherapy, *International Journal of Molecular Sciences*, 22, pp 1–25.
- Swain, S., Whaley, F. dan Ewer, M., 2003. Congestive Heart Failure in Patients Treated with Doxorubicin: A Retrospective Analysis of Three Trials, *American Cancer Soicety*, pp 2869–2879. <https://doi.org/10.1002/cncr.11407>.
- Swathi, B., Bhavika, D. dan Begum, N., 2015. Adverse Drug Reaction Profiles of Commonly Used Platinum Compounds in Cancer Chemotherapy, *International Journal of Basic & Clinical Pharmacology*, **4(2)**: 284–289. <https://doi.org/10.5455/2319-2003.ijbcp20150421>.
- Tse, T., Sehdev, S., Seely, J., Gravel, D.H., Clemons, M., Cordeiro, E. dan Arnaout, A., 2021. Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic: 1338–1347.
- U.S. Department of Health and Human Services, 2017. Common Terminology Criteria for Adverse Events (CTCAE) v5.0, *Cancer Therapy Evaluation Program (CTEP)*: 155.
- Vania, A., Hadiyanto, S., Miranti, I.P., Prajoko, Y.W. dan Istiadi, H., 2022. Histological and Clinical Stage Profiles of Young-Aged Breast Carcinoma, **3(1)**: 1–6.
- Vashakidze, N., Mebonia, N., Kereselidze, M. dan Zhizhilashvili, S., 2017. Factors Affecting Survival of Women Diagnosed With Breast Cancer in Georgia, *International Journal of Preventive Medicine*, **8**: 76–80.
- Wang, H., Zhang, N., Sun, Q., Zhao, Z., Pang, H., Huang, X. dan dkk., 2024. Comparison of the Efficacy of Taxanes With Carboplatin and Anthracyclines With Taxanes in Neoadjuvant Chemotherapy for Stage II–III Triple-Negative Breast Cancer: A Retrospective Analysis, *Journal of Cancer Research and Clinical Oncology*, **150(6)**: 1–14. <https://doi.org/10.1007/s00432-024-05738-x>.
- Wasserheit, C., Frazein, A., Oratz, R., Sorich, J., Downey, A., Hochster, H. dan dkk., 1996. Phase II Trial of Paclitaxel and Cisplatin in Women With Advanced Breast Cancer: An Active Regimen With Limiting Neurotoxicity, *Journal of Clinical Oncology*, **14(7)**: 1993–1999. <https://doi.org/10.1200/JCO.1996.14.7.1993>.

- Weng, A.Z., Wu, S., Luo, H., Du, Z., Li, X. dan dkk., 2021. Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis, **58**: 1–11. <https://doi.org/10.1177/00469580211056213>.
- Yuan, P., Kang, Y., Ma, F., Fan, Y., Wang, J., Wang, X. dan dkk., 2023. Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node-Positive Breast Cancer: A Randomized Clinical Trial, *JAMA Network Open*: 1–12. <https://doi.org/10.1001/jamanetworkopen.2023.0122>.
- Yulistiani, Utomob, F.N., Romadhonc, P.Z. dan Nareswarie, A.B., 2024. Analysis of Myelosuppression in Post-Chemotherapy Breast Cancer Patients.
- Zajaczowska, R., Kocot-K, M., Leppert, W., Mika, J. dan Wrzosek, A., 2019. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy, *International Journal of Molecular Sciences*, **20(6)**: 1451. <https://doi.org/10.3390/ijms20061451>.
- Van der Zanden, S.Y., Qiao, X. dan Neefjes, J., 2021. New Insights Into the Activities and Toxicities of the Old Anticancer Drug Doxorubicin, *FEBS Journal*. <https://doi.org/10.1111/febs.15583>.
- Zhang, C., Xu, C., Gao, X. dan Yao, Q., 2022. Platinum-Based Drugs for Cancer Therapy and Anti-Tumor Strategies, *Theranostics*, **12(5)**: 2115–2132. <https://doi.org/10.7150/thno.69424>.
- Zhang, P., Yin, Y., Mo, H., Zhang, B., Wang, X. dan Li, Q., 2016. Better Pathologic Complete Response and Relapse-Free Survival After Carboplatin Plus Paclitaxel Compared With Epirubicin Plus Paclitaxel as Neoadjuvant Chemotherapy for Locally Advanced Triple-Negative Breast Cancer: A Randomized Phase II Trial, **7(37)**.
- Zhong, X., 2020. Get to the Bottom of Lab Toxicity Grading: Challenges and Implementation of CTCAE Version 5, *Proceedings of the PHUSE Connect US 2020 Conference*, Paper DH16.